AstraZeneca eyes expansion
AstraZeneca Plc is looking to expand its presence in emerging markets outside China as the size and diversity of its portfolio offer new opportunities for the years ahead. This was one of the messages delivered to journalists by Pascal Soriot, the chief executive, on 10 February following the publication of the company’s 2025 results. After a year of product launches and higher demand for key medicines, the company delivered revenue of $58.7 billion in 2025, up by 9% in actual exchange rates and by 8% at constant rates.
